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We experienced the case of a 56-year-old male with B-lymphoid/myeloid lineage mixed phenotype acute
leukemia (MPAL). A cytogenetic analysis of the patient's bone marrow revealed a complex karyotype,
including der(9)t(7;9)(q11.2;p13). We identiﬁed an aberrant PAX5 transcript, including the exons 1A to
5 and the contiguous intron 5/6 sequence using the 3′ rapid ampliﬁcation of cDNA ends-polymerase
chain reaction method, and conﬁrmed their expression in the leukemic cells. Our case suggests that der
(9)t(7;9)(q11.2;p13) can cause the truncation of the PAX5 transcript, which is supposed to contribute to
the generation of MPAL, in addition to three previously reported types of PAX5 fusion.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mixed phenotype acute leukemia (MPAL) is a rare hematological
malignancy which is characterized by the generation of leukemic
blasts with multilineage potential. Genetic analyses revealed that the
BCR-ABL1 and KMT2A (MLL1) gene rearrangement in B-lymphoid/
Myeloid MPAL are frequently detected, resulting in the formation of
each subtype of MPAL. In addition, deletion 6 and 12p11.2 abnorm-
alities have been observed in multiple cases [1,2]. On the other hand,
the frequency and signiﬁcance of PAX5 gene alteration located on
9p13.2, which have been reported in B-progenitor acute lympho-
blastic leukemia (B-ALL), remains unknown in MPAL.
We herein report an MPAL patient with der(9)t(7;9)(q11.2;p13)
which generated a truncated PAX5 transcript.2. Case report
A 56-year-old male was referred to our hospital for evaluation
of leukocytosis (29,800109/L). A bone marrow examination
showed a marked proliferation of blasts (88.3%) that were negative
for myeloperoxidase (MPO) staining. These blasts were uniformlyLtd. This is an open access article u
ry Medicine, Tokai University
awa, Japan.
tsushita).positive for CD19, CD10, TdT, CD34, MPO and HLA-DR based on the
ﬁndings of ﬂow cytometry (Fig. 1A), thus suggesting the presence
of biphenotypic acute leukemia. A chromosomal analysis of the
bone marrow cells revealed a complex karyotype including the
derivative chromosome der(9)t(7;9)(q11.23;p13) (Fig. 1B). Tran-
scripts of BCR-ABL1, ETV6-RUNX1, E2A-PBX1, MLL-AF4, MLL-AF6,
MLL-AF9 and MLL-ENL were not detected. The patient was there-
fore diagnosed with MPAL of B-lymphoid/myeloid lineage (not
otherwise speciﬁed).3. Result and discussion
Three types of PAX5 fusion in B-ALL with t(7;9)(q11.2;p13) and
der(9)t(7;9)(q11.2;p13), including PAX5-ELN, PAX5-AUTS2 and
PAX5-POM12, have been reported thus far [3]. In order to analyze
the alteration of the PAX5 gene in the present case, we utilized the
3′ RACE-PCR method. We detected an aberrant PAX5 transcript,
including exons 1A to 5 and the contiguous intron 5/6 sequence.
The presumably truncated PAX5 protein was composed of 256
amino acids. It preserved the paired domain for DNA binding at
the N-terminus and acquired an aberrant C-terminus, instead of
the transactivation and inhibitory domains for transcription reg-
ulation. The expression of this transcript and wild-type transcript
(derived from a wild-type allele) in the leukemic blasts was con-
ﬁrmed by reverse transcription (RT)-PCR (Fig. 2).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The characterization of leukemic cells. A. A ﬂow cytometry analysis of the cellular surface markers. The blasts were found to be positive for CD19, CD10, TdT, CD34,
MPO and HLA-DR, while they were negative for CD13, CD33 and CD3. B. The cytogenetic analysis of our case. The karyotype panel shows 44, XY, -7, der(9)t(7;9)(q11.2;p13),
dic(12;17)(p11.2;p11.2), ?t(14;22)(q13,q13). The red arrow indicates the derivative chromosome der(9)t(7;9)(q11.23;p13). (For interpretation of the references to color in this
ﬁgure legend,the reader is referred to the web version of this article.)
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Fig. 2. The detection of the aberrant PAX5 transcript. A. A sequence chromatogram of the aberrant PAX5 transcript. B. The presumed structure of the truncated PAX5 protein.
The amino acid sequence derived from the intron 5/6 sequence (5/6) is indicated at the bottom of the panel. PD, paired domain; O, octapeptide; N, nuclear localization
sequence; HD, partial homeodomain; TAD, transactivation domain; ID, inhibitory domain. C. The expression of the truncated and wild-type PAX5, and GAPDH transcripts. The
arrowheads indicate the speciﬁc ampliﬁed bands. Burkitt cell lines, Daudi and Akata cells, were used as negative controls. Lanes 1, 6 and 11, the cDNA from the patient; lanes
2, 7 and 12, the cDNA from the Akata cells; lanes 3 and 8, the genomic DNA from the Akata cells; lanes 4, 9 and 13, the cDNA from the Daudi cells; lanes 5 and 10, the genomic
DNA from the Daudi cells. M, DNA size markers.
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supposed to be generated by chromosomal translocation without
the fusion partner gene at 9q13; The PAX gene was simply broken
at intron 5/6 without the supply of a splice acceptor site at the 3′
end of the intron, resulting in the in-frame transcription of the
unremoved intron sequence. An identical truncated transcript was
also detected in 3 B-ALL cases including a case with dic(9;16)(p13;
q11), but not der(9)t(7;9)(q11.2;p13) [4], suggesting that this ge-
netic alteration can be generated by genomic instability that is not
related to a speciﬁc rearrangement of PAX5.
The PAX5 gene encodes a transcriptional factor, which is spe-
ciﬁcally expressed at the early stages of B-cell differentiation and it
is required for B-cell development. Its dysregulation is involved in
the leukemogenesis of B-ALL. The PAX5 gene rearrangements ac-
count for approximately 2.5% of pediatric B-ALL cases [5]. A gen-
ome-wide analysis revealed that one-third of pediatric B-ALL cases
had somatic mutations in PAX5, which resulted in the generation
of a hypomorphic allele of the PAX5 gene [6]. Chemical and ret-
roviral mutagenesis signiﬁcantly increases the penetrance of B-ALL
in mice with a heterozygous loss-of-function mutation of PAX5 [7],
suggesting that the reduced expression and dysregulation of PAX5
function are closely related to the development of B-ALL.
However, the PAX5 function in bi-phenotypic B-lymphoid/
myeloid cells remains obscure; one study showed that ectopic
PAX5 expression was required for their maintenance [8]. Another
demonstrated that low-level PAX5 expression was required for
MPAL development [9]. To the best of the authors’ knowledge,
there are no other case reports of PAX5 gene or 9p13.2 abnorm-
alities in MPAL patients. The truncated PAX5 that was observed in
the present study behaves as a competitive inhibitor of wild-typePAX5 transcriptional activity [6], suggesting that the truncated
PAX5 may also contribute to the development of MPAL by in-
hibiting the function of wild-type PAX5.
The leukemogenesis of MPAL could be heterogeneous and even
complicated in some cases, because the development of MPAL
requires the inhibition of multilineage differentiation in leukemic
blasts. The complex karyotype in the present case indicates the
possible combined involvement of PAX5 inhibition derived from
truncated PAX5 and myeloid dysregulation provided by other ge-
netic abnormalities such as deletion 6 and 12p11.2 cytogenetic
aberrations resulting in the development of MPAL.
Regarding the technical effectiveness of RACE, RACE is not al-
ways successful at identifying chimeric transcripts even if PAX5
fusions are observed. As MPAL cases associated with 9p13 trans-
location are quite rare, a molecular analysis using these individual
cases are thus considered to be important to understand the ex-
pression and function of PAX fusion in MPAL leukemogenesis.
Therefore, comprehensive molecular techniques, such as RNA se-
quencing, may be helpful and informative for this purpose.
In conclusion, this is the ﬁrst case of MPAL with der(9)t(7;9)
(q11.2;p13), where an aberrant PAX5 transcript was detected.Authors' contributions
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